TSXV - Delayed Quote CAD

Waverley Pharma Inc. (WAVE.V)

Compare
0.0150 0.0000 (0.00%)
At close: October 15 at 1:36 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
NameTitlePayExercisedYear Born
Mr. Larry Thiessen M.B.A. President, CEO & Director 45k -- --
Mr. Haaris Uddin B.Com., CPA Chief Financial Officer 43.5k -- --

Waverley Pharma Inc.

4-1250 Waverley Street
Winnipeg, MB R3T 6C6
Canada
204 928 7907 https://www.waverleypharma.com
Sector:?
Healthcare
Industry:?
Biotechnology

Description

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. It also focuses on generic oncology injectable products. The company offers generic oncology products, such as temozolomide, capecitabine, and erlotinib. It also provides injectable generic chemotherapy drugs, such as pemetrexed for the treatment of non-small cell lung cancer and other indications; and bortezomib to treat multiple myeloma and other indications. In addition, the company develops PARP-1 inhibitors for cancer treatment. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

Corporate Governance

Waverley Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 25, 2024 at 9:00 PM UTC - November 29, 2024 at 9:00 PM UTC

Waverley Pharma Inc. Earnings Date

Recent Events

Related Tickers